ESMO 2024 - Daejin Abidoye
At ESMO 2024, AbbVie presented new data across their solid tumour pipeline, displaying the company’s potential as an emerging leader in solid tumours.
To find out more, web editor Nicole Raleigh spoke with Daejin Abidoye, VP and head of solid tumour oncology development at AbbVie, onsite in Barcelona.
Explaining the passion that drove him in his professional development in the oncology space, Abidoye sets out the landscape and discusses some of the new data, in particular from the ELAHERE phase 2 trial, as well as in non-small cell lung cancer and gastroesophageal adenocarcinoma.
It is, as Abidoye terms it, digging into the science for the good of patients.
With comment, also, on a greater focus on women’s cancers and what the future might hold for cancer research, be sure to tune into the video below to find out more from the congress. And if you missed them, catch up on earlier ESMO 2024 conversations with EVERSANA, Regeneron, Illumina, and Johnson & Johnson.
